Pretty much what the previous poster said. They are divided on aubagio and lemtrada. Each rep has 80% and 20% of the other . Those that are lemtrada reps, it's not going so hot. Just google sanofi Q3 quarter results, and it mentions over a 40% drop in lemtrada. It's a harder sell for sure. It can be a miracle drug for some, but can have some serious side effects too. If the job opening is mainly a lemtrada rep, check out the territory to know if it's mostly conservative neuros. If so, than it will be tough. My 2 cents. Good luck in whatever happens to you.
Appreciate the serious responses. I worked for Sanofi a while back and for whatever reason there was no option for advancement. After 15 years in sales Wanted to pursue other areas more clinically focused. This is a different division from what I was doing before. Thanks for previous/future feedback
14 Lemtrada rep layoffs announced on Tuesday. Remaining reps will sell only...no pull through responsibility. No change to Aubagio sales force.
ISM and BRM teams remain largely intact. May have lost 1 ISM, can’t remember. They will have responsibility to pull through Lemtrada, not the LABMs.
